Agilent Technologies Inc vs SPDR Gold Trust — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while SPDR Gold Trust trades at $403.57. The key difference: Agilent Technologies Inc pays a 0.69% dividend while SPDR Gold Trust pays none, and Agilent Technologies Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| A | GLD | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | — |
52-Week High | $157.20 | $495.90 |
52-Week Low | $110.24 | $305.27 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
GLD trades at $398.47, up 2.26% in the past 24 hours, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $399, with support at $397 and resistance at $400. Recent news highlights gold's rebound potential, citing central bank buying and softer Fed expectations as tailwinds. Financial ratios are unavailable, but the ETF's performance aligns with spot gold trends, which have gained momentum from geopolitical and macroeconomic factors.
The outlook for GLD is positive, with technical strength and supportive sentiment suggesting potential upside toward $402–$404 resistance. Risks include sensitivity to interest rate shifts and dollar strength, while analyst optimism centers on gold's safe-haven appeal. Investors should weigh ETF costs against physical gold alternatives, as momentum may hinge on sustained demand and economic data.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →